Financial Data and Key Metrics Changes - For the full year 2025, the company achieved 100% year-over-year growth with an adjusted EBITDA margin of 13%, a positive GAAP operating margin, and positive cash flow [6][26] - Total revenue in Q4 2025 was $96.1 million, representing a 113% year-over-year increase, with prenatal revenue at $86.9 million (up 98%) and oncology revenue at $9.1 million (up 736%) [29][21] - Gross margins improved to 71.4% in Q4 2025, a 14.3 percentage point increase year-over-year [25][31] Business Line Data and Key Metrics Changes - Test volumes grew by 51% year-over-year, reaching approximately 170,000 tests in Q4 2025 [20][33] - The average selling price (ASP) increased by 35% year-over-year to $495 for the full year 2025, with a significant sequential increase of $60 per test in Q4 [23][34] - Oncology revenue growth was driven by the adoption of Northstar Select and Response, with a quarter-over-quarter growth of 29% excluding true-up revenue [22][30] Market Data and Key Metrics Changes - The company reached an annualized revenue run rate of $384 million in Q4 2025, indicating strong market demand and growth potential [10][21] - The company has secured Medicare coverage for Northstar Select and signed contracts covering over 250 million lives in the U.S. [8][10] Company Strategy and Development Direction - The company aims to build a category-defining business and enter the S&P 500, focusing on innovation in prenatal and oncology diagnostics [11][46] - The launch of new products, including expanded fetal antigen NIPT and Northstar Select PGx, is expected to drive future growth [12][40] - The company emphasizes operational efficiency and cost reduction, achieving GAAP profitability while maintaining high growth rates [11][27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued growth, citing strong test volume momentum and the impact of new clinical guidelines on market adoption [37][38] - The company anticipates that the recent contract with UnitedHealthcare will enhance ASPs and reduce friction in patient access to tests [42][63] - Management believes that the current guidance for 2026 is conservative, with several growth drivers not fully reflected in the projections [35][79] Other Important Information - The company ended 2025 with approximately $496 million in cash and only $50 million in term debt, positioning it well for future growth [34][35] - The company achieved a significant milestone by going public during a challenging market environment, demonstrating resilience and execution capability [5][6] Q&A Session Summary Question: Awareness of UNITY among providers - Management noted that around 50% of providers are unaware of UNITY, indicating significant growth potential as awareness increases [49][50] Question: Conversations with health systems regarding MFMs - Management highlighted the importance of MFMs in driving test adoption and the ongoing discussions to increase uptake among larger health systems [52][53] Question: New provider metrics for Northstar - Management reported a record increase in active ordering providers in Q4, signaling strong growth potential for Q1 2026 [56][58] Question: Gross margin expectations - Management indicated that gross margins are expected to remain stable in the high 60% to low 70% range, without aggressive expectations for expansion [60] Question: Impact of UnitedHealthcare contract - Management expects higher ASPs from the in-network contract with UnitedHealthcare, which covers both prenatal and oncology products [63][65] Question: Competitive landscape and impact from Natera - Management stated that they have not seen any negative impact from competition, as evidenced by strong test volume growth and increased prenatal revenues [68]

Core Insights - BillionToOne, Inc. reported significant financial growth in Q4 2025 and raised its revenue guidance for 2026, reflecting strong demand for its molecular diagnostics products [1][4]. Financial Highlights - Total revenue for Q4 2025 was $96.1 million, a 113% increase from $45.1 million in Q4 2024 [5][7]. - Prenatal testing revenue reached $86.1 million in Q4 2025, up 99% from $43.2 million in Q4 2024 [5][11]. - Oncology testing revenue surged to $9.1 million in Q4 2025, an increase of 735% from $1.1 million in Q4 2024 [5][11]. - Gross profit margin improved to 71% in Q4 2025, compared to 57% in Q4 2024, driven by higher average selling prices (ASP) and reduced costs [8][12]. - Operating income was $10.3 million in Q4 2025, reversing an operating loss of $11.7 million in Q4 2024 [9][10]. Recent Operating Highlights - The company delivered 170,000 tests in Q4 2025, a 47% increase from 116,000 tests in Q4 2024 [5][6]. - BillionToOne launched new prenatal and oncology products in early 2026, including non-invasive prenatal tests for fetal antigen status and expanded applications for its Northstar platform [5][14]. - The company expects full-year 2026 revenue to be between $430 million and $445 million, representing a growth of 41% to 46% compared to 2025 [14]. Full Year 2025 Financial Results - Total revenue for 2025 was $305.1 million, a 100% increase from $152.6 million in 2024 [11][12]. - Gross profit for 2025 was $208.5 million, with a gross margin of 68%, up from 53% in 2024 [12][13]. - Net income available to common shareholders for 2025 was $2.9 million, or $0.14 per diluted share, compared to a net loss of $41.6 million in 2024 [13]. Cash Position - As of December 31, 2025, BillionToOne held approximately $496.0 million in cash and cash equivalents, indicating a strong liquidity position [13][22].

Core Insights - BillionToOne has launched two new add-on applications, Northstar PGx and Northstar Select CH, to enhance the Northstar Select platform for liquid biopsy testing, which is designed for advanced solid tumors [1] Group 1: Product Launch and Features - Northstar PGx provides pharmacogenomic insights into key variants in DPYD and UGT1A1, which are critical for fluoropyrimidine and irinotecan-based therapies, helping inform treatment planning without extending turnaround time [1] - Northstar Select CH addresses clonal hematopoiesis, which can lead to false positives in cfDNA testing, achieving over 99% accuracy in distinguishing tumor-derived alterations from non-tumor findings [1] - The integration of these applications into the Northstar workflow allows for comprehensive insights from a single blood draw, enhancing clinical decision-making without adding complexity [1] Group 2: Clinical Validation and Performance - Northstar Select demonstrated superior performance in detecting clinically actionable alterations, identifying 51% more pathogenic single nucleotide variants and 109% more copy number variants compared to other liquid biopsy tests [1] - The assay showed 98% concordance with results from digital droplet PCR, validating its sensitivity and accuracy in clinical settings [1] Group 3: Industry Context and Implications - The launch reflects a commitment to improving oncologists' ability to select appropriate therapies, thereby avoiding ineffective treatments and potential chemotherapy toxicity [1] - Recent guidelines emphasize the importance of broader testing, which aligns with the capabilities of Northstar PGx and Northstar Select CH, supporting the trend towards personalized medicine in oncology [1]